Method for diagnosing multiple sclerosis

Abstract

The present invention relates to methods for diagnosing multiple sclerosis in a subject, the method, comprising determining the level of phosphorylation of a marker in a biological sample from the subject, wherein the marker is selected from a1-antitrypsin (a1AT) and vitamin D binding protein (VDBP); and comparing the level of phosphorylation of the marker in the sample to a reference value.

Description

Technical field [0001] The present invention relates to a biomaker for multiple sclerosis. More specifically, the present invention relates to the use of these markers for the diagnosis of multiple sclerosis, the use for monitoring the course of the disease, the use in clinical trials or preclinical trials, and the use of drug screening and drug development. Background technique [0002] Multiple sclerosis (MS) is an autoimmune disease involving the nervous system, which affects nearly 2.5 million individuals worldwide, of which women are twice that of men. In the Western world, more than 80 people per 100,000 population are affected. The average age of onset of MS is 30 years; there are two age groups that are prone to disease. The majority of patients are 21 to 25 years old at the time of onset, and a small percentage of patients are 41 to 45 years old. [Krutze, JF., Neurology 30, 60-79 (1980)]. The economic burden associated with the disease is great. It has been estimated tha...

AI Technical Summary

Problems solved by technology

Many published studies use 2-D electrophoresis, which is cumbersome and often requires more protein than can be routinely obtained with CSF

In addition, proteins showing very low or high molecular weight, high hydrophobicity, low abundance and complete metabolome cannot be electrophoresed

Images